Immunodensity and mRNA expression of A2A adenosine, D 2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: Effect of antipsychotic treatment

Psychopharmacology

Volumn 206, Issue 2, 2009, Pages 313-324

  Urigüen, Leyre ^a,b   García Fuster, M Julia ^c,d,i   Callado, Luis F ^a,b   Morentin, Benito ^e   La Harpe, Romano ^f   Casadó, Vicent ^g,h   Lluis, Carmen ^g,h   Franco, Rafael ^g,h   García Sevilla, Jesús A ^c,d   Meana, J Javier ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^d Red Temática de Investigación Cooperativa en Salud Trastornos Adictivos   (Spain)

^e Basque Institute of Legal Medicine   (Spain)

^f UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^g UNIVERSITY OF BARCELONA   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Adenosine A2A receptor; Antipsychotic drugs; Cannabinoid receptor CB; Dopamine D2 receptor; Postmortem human brain; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A2A RECEPTOR; BENZODIAZEPINE; BIOLOGICAL MARKER; BIPERIDEN; CANNABINOID 1 RECEPTOR; CARBAMAZEPINE; DOPAMINE 2 RECEPTOR; ENDOCANNABINOID; FLUOXETINE; MESSENGER RNA; NEUROLEPTIC AGENT; TRAZODONE; VENLAFAXINE;

ARTICLE; AUTOPSY; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNODETECTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DENSITY; SCHIZOPHRENIA; SUICIDE; WESTERN BLOTTING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; POSTMORTEM CHANGES; RECEPTOR, ADENOSINE A2A; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; SCHIZOPHRENIA; SUICIDE; YOUNG ADULT;

EID: 69549105668     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1608-2     Document Type: Article

References (46)

1. LF Agnati S Ferre C Lluis R Franco K Fuxe 2003 Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons Pharmacol Rev 55 509 550 10.1124/pr.55.3.2 (Pubitemid 37013214)
2. MS Buchsbaum BT Christian DS Lehrer TK Narayanan B Shi J Mantil E Kemether TR Oakes J Mukherjee 2006 D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia Schizophr Res 85 232 244 10.1016/j.schres.2006.03.042 (Pubitemid 43947535)
3. M Canals D Marcellino F Fanelli F Ciruela P de Benedetti SR Goldberg K Neve K Fuxe LF Agnati AS Woods S Ferre C Lluis M Bouvier R Franco 2003 Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer J Biol Chem 278 46741 46749 10.1074/jbc.M306451200 (Pubitemid 37452253)
4. 1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids Neuropsychopharmacology 32 2249 2259 10.1038/sj.npp.1301375 (Pubitemid 47587686)
5. P Carriba G Navarro F Ciruela S Ferré V Casadó L Agnati A Cortés J Mallol K Fuxe EI Canela C Lluís R Franco 2008 Detection of heteromerization of more than two proteins by sequential BRET-FRET Nature Methods 5 727 733 10.1038/nmeth.1229
6. B Dean S Sundram R Bradbury E Scarr D Copolov 2001 Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use Neuroscience 103 9 15 10.1016/S0306-4522(00)00552-2 (Pubitemid 32304342)
7. B Dean G Pavey E Scarr K Goeringer DL Copolov 2004 Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia Life Sci 74 3115 3131 10.1016/j.lfs.2003.11. 004 (Pubitemid 38470104)
8. J Deckert M Brenner N Durany R Zöchling W Paulus G Ransmayr T Tatschner W Danielczyk K Jellinger P Riederer 2003 Up-regulation of striatal adenosine A(2A) receptors in schizophrenia Neuroreport 14 313 316 10.1097/01.wnr:0000058242.21747.04
9. C Deng M Han XF Huang 2007 No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia Neurosci Bull 23 341 347 10.1007/s12264-007-0051-9
10. SM Eggan T Hashimoto DA Lewis 2008 Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia Arch Gen Psychiatry 65 772 784
11. S Ferré F Ciruela AS Woods C Lluis R Franco 2007 Functional relevance of neurotransmitter receptor heteromers in the central nervous system Trends Neurosci 30 440 446 10.1016/j.tins.2007.07.001 (Pubitemid 47381459)
12. S Ferré SR Goldberg C Lluis R Franco 2009 Looking for the role of cannabinoid receptor heteromers in striatal function Neuropharmacology 56 226 234 10.1016/j.neuropharm.2008.06.076
13. TM Gerald GR Ward AC Howlett SO Franklin 2006 CB1 knockout mice display significant changes in striatal opioid peptide and D4 dopamine receptor gene expression Brain Res 1093 20 24 10.1016/j.brainres.2006.03.088 (Pubitemid 43946401)
14. M Glass M Dragunow RL Faull 1997 Cannabinoid receptors in the human brain: a detailed anatomical and quantitative auroradiographic study in the fetal, neonatal and adult human brain Neuroscience 77 299 318 10.1016/S0306-4522(96)00428-9 (Pubitemid 27079604)
15. L Gimenez-Llort SN Schiffmann T Shmidt L Canela L Camon M Wassholm M Canals A Terasmaa A Fernández-Teruel A Tobeña E Popova S Ferré L Agnati F Ciruela E Martínez J Scheel-Kruger C Lluis R Franco K Fuxe M Bader 2007 Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain Neurobiol Learn Mem 87 42 56 10.1016/j.nlm.2006.05.004 (Pubitemid 44755268)
16. O Guillin A Abi-Dargham M Laruelle 2007 Integrating the neurobiology of schizophrenia Int J Neurobiol 78 377 395 10.1016/S0074-7742(06)78001-1
17. N Hamdani J-P Tabeze N Ramoz J Ades M Hamon Y Sarfati C Boni P Gorwood 2008 The CNR1 gene as a pharmacogenetic factor for antipsychotic rather than a susceptibility gene for schizophrenia Eur Neuropsychopharmacology 18 34 40 10.1016/j.euroneuro.2007.05.005 (Pubitemid 350218211)
18. J Hillion M Canals M Torvinen V Casado R Scott A Terasmaa A Hansson S Watson ME Olah J Mallol EI Canela M Zoli LF Agnati CF Ibanez C Lluis R Franco S Ferre K Fuxe 2002 Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors J Biol Chem 277 18091 18097 10.1074/jbc.M107731200 (Pubitemid 34967623)
19. 2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67 1697 1704 10.1124/mol.104.006882 (Pubitemid 40594170)
20. 2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects Biol Psychiatry 65 1024 1031 10.1016/j.biopsych.2008.12.029
21. D Koethe IC Llenos JR Dulay C Hoyer EF Torrey FM Leweke S Weis 2007 Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression J Neural Transm 114 1055 1063 10.1007/s00702-007-0660-5
22. M Laruelle 1998 Imaging dopamine transmission in schizophrenia. A review and meta- analysis Q J Nucl Med 42 211 221
23. DA Lewis T Hashimoto DW Volk 2005 Cortical inhibitory neurons and schizophrenia Nat Rev Neurosci 6 312 324 10.1038/nrn1648 (Pubitemid 40469985)
24. JZ Li MP Vawter DM Walsh H Tomita SJ Evans PV Choudary JF Lopez A Avelar V Shokoohi T Chung O Mesarwi EG Jones SJ Watson H Akil WE Bunney Jr RM Myers 2004 Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions Hum Mol Genet 13 609 616 10.1093/hmg/ddh065 (Pubitemid 38379850)
25. M López de Jesús J Sallés JJ Meana LF Callado 2006 Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates Neuroscience 140 635 643 10.1016/j.neuroscience.2006.02. 024
26. 2 heteromers. A combined neurochemical and behavioral analysis Neuropharmacology 54 815 823 10.1016/j.neuropharm.2007.12.011
27. 2 dopamine receptor-mediated motor behaviors Neuropsychopharmacology 33 1667 1679 10.1038/sj.npp.1301558 (Pubitemid 351684717)
28. JH Meador-Woodruff V Haroutunian P Powchik M Davidson KL Davis SJ Watson 1997 Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia Arch Gen Psychiatry 54 1089 1095
29. HY Meltzer L Arvanitis D Bauer W Rein 2004 Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder Am J Psychiatry 161 975 984
30. S Miyamoto GE Duncan CE Mar JA Lieberman 2005 Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychtic drugs Mol Psychiatry 10 79 104 10.1038/sj.mp.4001556 (Pubitemid 40139590)
31. TH Moore S Zammit A Lingford-Hughes TR Barnes PB Jones M Burke G Lewis 2007 Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review Lancet 370 319 328 10.1016/S0140-6736(07)61162-3 (Pubitemid 47094993)
32. CJA Morgan HV Curran 2008 Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis Br J Psychiatry 192 306 307 10.1192/bjp.bp.107.046649 (Pubitemid 351692406)
33. G Navarro P Carriba J Gandía F Ciruela V Casadó A Cortés J Mallol EI Canela C Lluis R Franco 2008 Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer ScientificWorldJournal 8 1088 1097 10.1100/tsw.2008.136
34. KA Newell C Deng XF Huang 2006 Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia Exp Brain Res 172 556 560 172:556-560.10.1007/s00221-006-0503-x (Pubitemid 43989359)
35. DL Rosin A Robeva RL Woodard PG Guyenet J Linden 1998 Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system J Comp Neurol 401 163 186 10.1002/(SICI)1096-9861(19981116)401:2<163::AID- CNE2>3.0.CO;2-D (Pubitemid 28481960)
36. P Seeman C Ulpian C Bergeron P Riederer K Jellinger E Gabriel GP Reynolds WW Tourtellotte 1984 Bimodal distribution of dopamine receptor densities in brains of schizoprenics Science 225 728 731 10.1126/sicence.6147018
37. high dopamine receptors Synapse 60 319 346 10.1002/syn.20303 (Pubitemid 44134353)
38. J Seifert S Ossege HM Emrich U Schneider M Stuhrmann 2007 No association of CNR1 gene variations with susceptibility to schizophrenia Neurosci Lett 426 29 33 10.1016/j.neulet.2007.08.008 (Pubitemid 47444497)
39. N Solowij PT Michie 2007 Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32 30 52
40. T Suhara Y Okubo F Yasuno Y Sudo M Inoue T Ichimiya Y Nakashima K Nakayama S Tanada K Suzuki C Halldin L Farde 2002 Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia Arch Gen Psychiatry 59 25 30 (Pubitemid 34044401)
41. 1 receptor in the rat nucleus accumbens Naunyn Schmiedeberg's Arch Pharmacol 371 428 433 10.1007/s00210-005- 1074-2 (Pubitemid 41187515)
42. H Takahashi M Higuchi T Suhara 2006 The role of extrastriatal dopamine D2 receptors in schizophrenia Biol Psychiatry 59 919 928 10.1016/j.biopsych.2006. 01.022
43. 2/3 receptor density and distribution in drug-naive schizophrenic patients Mol Psychiatry 8 453 455 10.1038/sj.mp.4001334 (Pubitemid 36609670)
44. H Ujike M Takaki K Nakata Y Tanaka T Takeda M Kodama Y Fujiwara A Sakai S Kuroda 2002 CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia Mol Psychiatry 7 515 518 10.1038/sj.mp.4001029 (Pubitemid 34712904)
45. 2 densities and the schizophrenia brain Schizophr Res 32 201 206 10.1016/S0920-9964(98)00041-3 (Pubitemid 28383778)
46. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 28 355 360 10.1016/j.pnpbp.2003.11.005 (Pubitemid 38130143)